Sai Parenteral's IPO Review: A Quiet Listing That Turned Into a Rich Valuation Story

Quick Answer

Sai Parenteral's IPO had an unglamorous start that has since become a genuinely rich valuation story. The Hyderabad based pharmaceutical formulations and CDMO company was only lightly subscribed at around 1.05 times, with retail demand notably weak at just 0.12 times, and the grey market premium sat at zero throughout. It listed on 2 April 2026 at Rs 400 on the NSE, a modest 2.04% premium over the Rs 392 issue price, during a period when the Iran-Israel-US conflict was rattling global markets and most 2026 mainboard IPOs were debuting at a discount. Since then the stock has surged well past Rs 600, but that rise has run well ahead of the company's actual revenue growth, leaving the stock at a rich 70 to 110 times earnings depending on which period's profit you use.

Sai Parenteral's IPO Key Details at a Glance

What Does Sai Parenteral's Ltd Do?

Sai Parenteral's, incorporated in 2001 and headquartered in Hyderabad, is a diversified pharmaceutical formulations company operating across two segments: Branded Generic Formulations sold domestically, and Contract Development and Manufacturing Organisation, or CDMO, services for global clients. Its product range spans injectables, tablets, capsules, liquid orals and ointments across therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins and minerals, and dermatology.

The manufacturing base. The company operates five facilities, four in Hyderabad, Telangana and one in Ongole, Andhra Pradesh, carrying WHO-GMP, TGA-Australia and PIC/S accreditations, credentials that matter for supplying regulated export markets. You can follow its live price and post listing updates on the IPO GMP Live homepage.

The export and acquisition angle. Since entering export markets in FY23, the company has built a presence in Australia, New Zealand, Southeast Asia, the Middle East and Africa, and through its Singapore subsidiary it has moved to acquire Noumed Pharmaceuticals Pty Limited in Australia, a genuine step toward deeper regulated-market integration rather than pure export sales.

How Strong Are Sai Parenteral's Financials, and Does the Price Match Them?

The growth here is real but modest, not explosive. Revenue rose from Rs 155 crore in FY24 to Rs 164 crore in FY25, only about 5.6%, and the six months to September 2025 brought in Rs 89 crore, annualising to roughly Rs 178 crore, a continuation of steady, single digit growth rather than acceleration.

Profit did jump once, and then flattened. Net profit rose 71% from Rs 8.42 crore in FY24 to Rs 14.43 crore in FY25, a genuinely strong one-year improvement. But the six months to September 2025 delivered Rs 7.76 crore, which annualises to around Rs 15.5 crore, essentially flat against FY25 rather than continuing to compound. The profit jump that justified some of the IPO enthusiasm has not repeated itself since listing.

This is the heart of the valuation concern. At listing, the P/E was already a rich 113.8 times FY25 earnings. With the stock now above Rs 600, well past its own 52-week high as recorded on some trackers, the multiple has stretched further even as the underlying profit growth has flattened rather than accelerated. For comparison, listed peers Gland Pharma trade at about 44.7 times earnings and Innova Captab at around 32.5 times, both considerably cheaper than where Sai Parenteral's now sits. The company's 24.18% EBITDA margin and 28.92% ROCE, the highest in its peer group, are genuine operational strengths, but they do not on their own explain a valuation this far above comparable, larger pharma companies.

Why Did the Stock Rally So Hard Despite Weak Subscription and Zero GMP?

The disconnect between the muted IPO reception and the subsequent price action is the story worth understanding:

• A positive listing in a falling market stood out. With 58% of 2026's mainboard IPOs debuting at a discount amid the Iran-Israel-US conflict, simply listing above issue price, even by a modest 2%, was read by some as a signal of underlying resilience, which may have drawn buying interest once broader market sentiment stabilised.
• The CDMO and export growth narrative attracted a re-rating. The Noumed Pharmaceuticals acquisition and the regulated-market export push into Australia and other markets gave the market a growth story to price in advance of it showing up fully in reported numbers, a classic case of paying today for tomorrow's expected CDMO scale-up.
• Anchor lock-ins have now passed without disruption. Fifty percent of the anchor shares were released from lock-in on 28 April 2026 and the remaining fifty percent on 27 June 2026, both dates now behind us, and the fact that the stock continued climbing through both release windows suggests anchor investors were not dumping shares, itself a mildly reassuring signal.
• Thin retail participation left more of the float in fewer hands. With retail demand at just 0.12 times, a larger share of the stock likely sits with institutions and HNIs who bid more aggressively, and thinner free float distribution can accentuate price moves in both directions.

Should You Buy Sai Parenteral's Shares Now?

The stock trades above Rs 600 against a Rs 392 issue price. The honest read by investor type:

• Conservative investors: A 70 to 110 times earnings multiple on a company growing revenue at single digit rates, whose FY25 profit jump has already flattened in the following half year, is not a low risk entry regardless of the strong margins. Peers trading at less than half this multiple offer a more reasonably priced way to access the same sector.
• Moderate investors: The CDMO expansion and Noumed acquisition are genuine long-term growth levers, but they need to show up in reported revenue and profit, not just in the narrative, before the current price is justified. Watching the next two to three quarters, as several reviewers suggested right after listing, remains the sensible approach.
• Aggressive investors: If the Australia acquisition and CDMO scale-up genuinely accelerate growth from here, today's price could eventually be justified. But this is a bet on a story converting into numbers that have not yet arrived, at a valuation that already assumes a great deal of that conversion happening successfully.

Honest take. Sai Parenteral's is a case where the market has moved well ahead of the fundamentals. The company itself is solid, strong margins, the highest ROCE in its peer set, real regulated-market accreditations and a credible CDMO growth plan. But revenue growth has been in the single digits, and the one big profit jump that partly justified the IPO pricing has already flattened in the first half year as a listed company. At 70 to over 100 times earnings, against peers trading at less than half that, the current price is pricing in successful execution of the CDMO and Australia strategy well before the numbers confirm it is working.

Where Did the IPO Money Go?

The Rs 408.79 crore issue combined a fresh raise of Rs 285 crore with an offer for sale of Rs 123.79 crore. Of the fresh proceeds, the largest allocation, Rs 110.80 crore, funds capacity expansion and upgrades to manufacturing facilities. Rs 35.64 crore goes toward the Noumed Pharmaceuticals acquisition in Australia through the company's Singapore subsidiary, Rs 33 crore to working capital, Rs 18.02 crore to establishing a new R&D centre, and Rs 14.30 crore to repaying borrowings, with the balance covering general corporate purposes and issue expenses. This is a genuinely growth-oriented allocation, capacity, R&D and an international acquisition together account for the bulk of the fresh money, which supports the long-term CDMO thesis even if the near-term numbers have yet to catch up to the valuation.

Contact Details

• Company: Sai Parenteral's Ltd.
• Location: Registered office in Gachibowli, Hyderabad, Telangana; manufacturing facilities in Hyderabad (4) and Ongole, Andhra Pradesh (1)
• Business: Pharmaceutical formulations across Branded Generics and CDMO segments, injectables, tablets, capsules, liquid orals and ointments, with WHO-GMP, TGA-Australia and PIC/S accreditations
• Promoters: Anil Kumar Karusala, Vijitha Gorrepati, Karusala Aruna
• Registrar: Bigshare Services Pvt. Ltd.
• Lead Manager: Arihant Capital Markets Ltd.
• Listing: BSE and NSE (Mainboard)

This page is not investment advice. GMP is indicative only and unofficial. Please consult a SEBI registered financial advisor before investing.